HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 51.98% from the company’s current price.

Several other analysts have also recently issued reports on the company. StockNews.com cut Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday, December 28th. Benchmark upped their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Rodman & Renshaw restated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Stock Down 2.2 %

Shares of NYSE:EBS opened at $9.87 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The business has a fifty day moving average of $9.34 and a two-hundred day moving average of $9.12. The stock has a market cap of $534.80 million, a P/E ratio of -2.41 and a beta of 1.60. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10.

Hedge Funds Weigh In On Emergent BioSolutions

Hedge funds have recently modified their holdings of the business. State Street Corp grew its position in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP acquired a new position in Emergent BioSolutions in the 3rd quarter valued at about $9,296,000. Millennium Management LLC grew its position in Emergent BioSolutions by 5.8% in the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock valued at $6,454,000 after acquiring an additional 52,144 shares in the last quarter. American Century Companies Inc. grew its position in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after acquiring an additional 623,201 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after acquiring an additional 316,700 shares in the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.